Why the study?
Despite the high mortality associated with angiosarcoma, its low prevalence has limited sample sizes in prior studies.
Population
346 patients (359 tumor samples) with angiosarcoma
Design
Multi-institutional registry-based analysis
Authors
Loading...
Should not yet guide therapy in angiosarcoma; leaves open prospective trials to assess these alterations as targets.
This large genomic analysis of angiosarcoma identified recurrent alterations in TP53, KDR, PIK3CA, and MYC, suggesting potential future therapeutic targets.
Leach et al. (2025) studied this question.